Compare Devon Energy Corp (DVN) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Eli Lilly And Co — how do they compare? Devon Energy Corp trades at $48.89 (market cap $53.81B), while Eli Lilly And Co trades at $1,170.5 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 19.3× Devon Energy Corp's market cap, and Devon Energy Corp pays the higher dividend (2.62%). Which is the better fit depends on your goals — on Pluang, investors hold Devon Energy Corp for 136 Days and Eli Lilly And Co for 93 Days on average.
| DVN | LLY | |
|---|---|---|
Market Cap | $53.81B | $1.04T |
Volume | 11,556,740 | 3,064,878 |
Sector | Energy | Health |
52-Week High | $52.07 | $1.28K |
52-Week Low | $31.74 | $799.57 |
Typical Hold Time | 136 Days | 93 Days |
Enterprise Value | $64.55B | $1.09T |
Dividend Yield | 2.62% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $47.88, down 0.29% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $62.40 implying significant upside. Recent earnings have been mixed, with a Q2 2026 beat but a Q1 miss, while fundamentals show solid profitability with a 16.67% net income margin and attractive valuation multiples. Activist investor pressure for strategic alternatives, including a potential sale, has been a key recent development.
The outlook is positive, supported by strong analyst buy ratings (71.87%) and projected revenue growth to $19.7B in 2026. Key risks include oil price volatility, execution of asset sales, and rising debt levels, but the current valuation and cash flow generation present a compelling opportunity for value-oriented investors.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.
Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
